Promising combo shows survival edge in kidney cancer
NCT ID NCT02853331
First seen Feb 02, 2026 · Last updated May 24, 2026 · Updated 14 times
Summary
This study tested whether combining two drugs—pembrolizumab (an immunotherapy) and axitinib (a targeted therapy)—works better than the standard drug sunitinib alone for people with advanced kidney cancer. Over 860 participants received either the combination or sunitinib as their first treatment. The goal was to see if the combo could slow cancer growth and help people live longer. Results showed the combination improved both progression-free and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.